Newsbenzinga
BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…